enGene (ENGN) to Release Earnings on Tuesday

enGene (NASDAQ:ENGN - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, June 10th. Analysts expect enGene to post earnings of ($0.48) per share for the quarter.

enGene Stock Performance

ENGN traded down $0.37 on Wednesday, hitting $3.83. 66,606 shares of the company's stock were exchanged, compared to its average volume of 131,274. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. The stock has a fifty day moving average of $3.94 and a two-hundred day moving average of $5.72. enGene has a twelve month low of $2.65 and a twelve month high of $11.00. The firm has a market cap of $195.25 million, a PE ratio of -6.60 and a beta of -0.36.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on ENGN shares. Morgan Stanley reduced their price objective on enGene from $37.00 to $34.00 and set an "overweight" rating for the company in a research report on Tuesday, March 11th. JMP Securities reaffirmed a "market outperform" rating and issued a $18.00 price objective on shares of enGene in a report on Tuesday, April 29th. HC Wainwright reissued a "buy" rating and set a $25.00 target price on shares of enGene in a research note on Tuesday, March 11th. Piper Sandler began coverage on enGene in a report on Tuesday, February 18th. They set an "overweight" rating and a $26.00 price target on the stock. Finally, UBS Group lowered enGene from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $34.00 to $7.00 in a report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $23.29.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.